DELIVEREL
LIVE

Serial Number

88656821

Owner

FUJIFILM CORPORATION

Attorney

Suzanne M. Hengl

Filing Date

Oct 16, 2019

Add to watchlist:

No watchlists yet
View on USPTO

DELIVEREL Trademark

Serial Number: 88656821 • Registration: 6641823

DELIVEREL is a trademark filed by FUJIFILM CORPORATION on October 16, 2019. The trademark is classified under Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently registered and active.

Owner Contact Info

FUJIFILM CORPORATION (524 trademarks)

26-30, NISHIAZABU 2-CHOME, MINATO-KU
TOKYO , JP

Entity Type: 03

Trademark Details

Filing Date

October 16, 2019

Registration Date

February 15, 2022

Published for Opposition

September 7, 2021

Goods & Services

Processing of liposome pharmaceutical preparations composed of nucleotides for use in manufacture; processing of liposome preparations composed of nucleotides for use in manufacture; processing of pharmaceutical preparations for drug delivery system composed of liposomes for delivering nucleotides for use in manufacture; processing of microcapsules for drug delivery system composed of liposomes for delivering nucleotides for use in manufacture; processing of chemicals for drug delivery system composed of liposomes for delivering nucleotides for use in manufacture; custom manufacture and processing of pharmaceuticals and chemicals for others; custom manufacture and processing of cosmetics and soaps for others

Drug delivery agents in the form of dissolvable films, coatings for tablets and capsules composed of liposomes that facilitate the delivery of pharmaceutical preparations and nucleotides; Drug delivery agents in the form of capsules that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of microcapsules composed of liposomes for the delivery of pharmaceutical preparations and nucleotides; Drug delivery agents in the form of dissolvable films, coatings for tablets and capsules composed of liposome preparations for use in the delivery and release of pharmaceutical preparations; Drug delivery agents in the form of dissolvable films, coatings for tablets and capsules composed of liposome reagents for transfection of cells, only for medical and veterinary use; dietary supplements; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; dietary supplements for animals; Drug delivery agents in the form of dissolvable films, coatings for tablets and capsules composed of antibodies for use in disease testing and pathology diagnosis

Cosmetics; skin soap; bath soap; deodorant soap; dishwasher detergents; laundry detergents; detergents for household use; dentifrices; fragrances and perfumery; essential oils for flavoring food and beverages; incense

Chemical preparations for scientific purposes, other than for medical or veterinary use; industrial chemicals; Chemicals for use in industry and science; chemical compositions for developing, printing and enlarging photographs; plant growth regulating preparations; fertilizers; Fatty acids used in the manufacture of pharmaceutical and cosmetic products; Biochemicals, namely, liposomes used in the manufacture of pharmaceutical and cosmetic products; Chemicals additives, namely, liposomes for use in the manufacture of pharmaceutical and cosmetic products; Biochemicals, namely, polyclonal antibodies and monoclonal antibodies for in vitro scientific or research use; Biochemicals, namely, polyclonal antibodies and monoclonal antibodies used in analyzing and detecting certain toxins or diseases for laboratory or research use; anti cancer nucleic acid for laboratory use; anti aging nucleic acid for laboratory use; anti-inflammatory nucleic acid for laboratory use; Biomedical compounds, namely, anti cancer peptide substrates used in analyzing and detecting certain toxins for laboratory use; Biomedical compounds, namely, anti aging peptide substrates used in analyzing and detecting certain toxins for laboratory use; Biomedical compounds, namely, anti-inflammatory peptide substrates used in analyzing and detecting certain toxins for laboratory use; Biomedical compounds, namely, anti cancer compounds used in analyzing and detecting certain toxins for laboratory use; Biomedical compounds, namely, anti aging compounds used in analyzing and detecting certain toxins for laboratory use; anti-inflammatory compounds for laboratory use; Biomedical compounds, namely, peptides used in analysis of angiogenesis for laboratory use, other than for medical or veterinary use; cells for laboratory research and scientific use, other than for medical or veterinary use; Biochemicals, namely, liposome use for transfection of cells for scientific or research use; Chemical reagents, other than for medical or veterinary purposes

Filing History

REGISTERED-PRINCIPAL REGISTER
Feb 15, 2022 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jan 7, 2022 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 7, 2022 AITU
NOTICE OF ALLOWANCE CANCELLED
Nov 30, 2021 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Nov 30, 2021 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 2, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 7, 2021 NPUB
PUBLISHED FOR OPPOSITION
Sep 7, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 18, 2021 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Aug 2, 2021 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jul 30, 2021 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 27, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 26, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 26, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 26, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 24, 2021 GNRN
NON-FINAL ACTION E-MAILED
May 24, 2021 GNRT
NON-FINAL ACTION WRITTEN
May 24, 2021 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 29, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 29, 2021 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 26, 2021 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 1, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 1, 2021 GNSL
SUSPENSION LETTER WRITTEN
Feb 1, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 25, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 25, 2021 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 22, 2021 ERSI
ASSIGNED TO EXAMINER
Aug 31, 2020 DOCK
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jul 23, 2020 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jul 23, 2020 GNSI
SUSPENSION INQUIRY WRITTEN
Jul 23, 2020 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 18, 2020 RCCK
ASSIGNED TO LIE
Jun 29, 2020 ALIE
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 5, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 5, 2019 GNSL
SUSPENSION LETTER WRITTEN
Dec 5, 2019 CNSL
ASSIGNED TO EXAMINER
Dec 3, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 20, 2019 NWOS
NEW APPLICATION ENTERED
Oct 19, 2019 NWAP